鶹Ƶ

Skip to main content
  • Home
  • 鶹Ƶ
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Students
    • All Topics
  • Contact
  • Submit
STEM
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • University Statements
  • 鶹ƵUniversity Impact
  • |
  • The Peel
Sections
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • University Statements
  • 鶹ƵUniversity Impact
  • |
  • The Peel
  • Home
  • 鶹Ƶ
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Students
    • All Topics
  • Contact
  • Submit
STEM

Keeping SARS2 Out of the Cell

Tuesday, February 23, 2021, By Dan Bernardi
Share
BioInspiredCollege of Arts and SciencesfacultyNational Science FoundationResearch and CreativeSTEM

Epifluorescence image of extracellular vimentin (green), here seen with the protein actin (red) and DNA (blue), speeds up delivery of SARS2 to the cell. (Courtesy: Maxx Swoger and Alison Patteson)

As vaccines are distributed worldwide to fight the pandemic, important research at 鶹ƵUniversity may uncover ways to block it and similar viruses in the future. Alison Patteson, assistant professor of physics, and Jennifer Schwarz, associate professor of physics, recently completed a study that tested the ability of certain antibodies to block SARS2 from entering cells by way of cell-surface vimentin, a protein that is also a pathway for the virus to enter the body. The study was funded by a $196,000 National Science Foundation RAPID Response Research initiative grant.

While bacterial pathogens such as Salmonella and E. coli can survive on their own without a host cell to infect, viruses must get inside cells to replicate and use that cell’s own biochemical machinery to build new virus particles and spread to other cells. But in order for this process to start, the virus must find a way to first adhere to the surface of a cell.

There are two main ways the SARS2 virus enters human cells. When someone infected with coronavirus coughs, sneezes, sings, talks, or breathes, the tiny particles they expel are projected into the air. Then, another person inhales those particles into their nose, mouth, airways and lungs. When these particles enter the lungs, they begin searching for cells to attach to. In the case of the SARS2, a spike protein in the virus searches for a cellular receptor called ACE2 to adhere to. Think of the spike protein and cellular receptor like two pieces of Velcro. Once attached, the virus can enter the cell through membrane fusion (where the virus particle merges with the host cell) or endocytosis (where the virus particle is engulfed into the host cell).

Patteson, Schwarz and a team of researchers have identified an important protein in this process called vimentin. Vimentin is a key internal structural protein present in many cell types that protects its nucleus against deformation, rupture and DNA damage. They have uncovered that this molecule also lives on the outside surface or the cell, where it adheres to the spike protein in the virus and helps speed up its delivery to the ACE2 receptor of the cell, acting as a mediator. Finding an antibody that would prevent vimentin and its attached virus spike protein from connecting to the cell surface could halt one of the common ways people contract COVID-19.

Alison Patteson and Jennifer Schwarz

Patteson and Schwarz became interested in investigating this topic after reading reports of vimentin being implicated in SARS1, a respiratory illness that affected many people worldwide in 2003. Their cutting-edge research is one of the first to show that antibodies against vimentin can block cellular uptake of the SARS2 coronavirus.

In a research collaboration with Nascent Biotech, a company currently developing human anti-vimentin antibodies for clinical cancer studies, they reported positive results demonstrating that the same antibodies against vimentin can block up to 80% of host cell invasion. Their results suggest a new target and therapeutic strategy to reduce SARS-CoV-2 attachment and entry into the cell, which could reduce the spread of SARS2.

The Patteson Group is now in the planning stages to test the antibody in living models. According to Dr. Navpaul Singh, Nascent Biotech chief medical officer over viral research, if the anti-vimentin antibody prevents uptake of the virus in animal models, the next logical step would be to test it in humans. “If we have success in humans, we then have a successful therapeutic strategy against COVID-19,” he notes.

Patteson says potential therapeutics could be administered in two ways. One is a nasal spray, which would be used after possible exposure to the virus. The spray would reduce or prevent the virus-carrying vimentin from attaching to the surface of a cell. Another is intravenously, where the antibody would be combined with an antiviral medication like Remdesivir, which prevents the replication of the virus for patients already suffering from COVID-19. Anti-vimentin antibodies could prevent further uptake of the virus to cells in the body.

While these treatments are still in the early stages of development, the team’s breakthrough shines a light on a new way to halt SARS2 and future viruses from entering the cell. Preventing viral invasion of cells using anti-vimentin antibodies could be another tool, along with vaccines, to eventually bring the virus—and future pandemics—under control.

  • Author

Dan Bernardi

  • Recent
  • 鶹ƵStage Hosts Inaugural Julie Lutz New Play Festival
    Wednesday, May 28, 2025, By News Staff
  • Timur Hammond’s ‘Placing Islam’ Receives Journal’s Honorable Mention
    Tuesday, May 27, 2025, By News Staff
  • Expert Available to Discuss DOD Acceptance of Qatari Jet
    Thursday, May 22, 2025, By Vanessa Marquette
  • 鶹ƵUniversity 2025-26 Budget to Include Significant Expansion of Student Financial Aid
    Wednesday, May 21, 2025, By News Staff
  • Light Work Opens New Exhibitions
    Wednesday, May 21, 2025, By News Staff

More In STEM

University’s Dynamic Sustainability Lab and Ireland’s BiOrbic Sign MOU to Advance Markets for the Biobased Economy

This month at the All Island Bioeconomy Summit held in Co. Meath, Ireland, it was announced that BiOrbic, Research Ireland Centre for Bioeconomy, comprising 12 leading Irish research universities in Ireland, signed a joint memorandum of understanding (MOU) with the Dynamic Sustainability…

Professor Bing Dong Named as the Traugott Professor of Mechanical and Aerospace Engineering

The College of Engineering and Computer Science has named Bing Dong as the Traugott Professor of Mechanical and Aerospace Engineering. This endowed professorship is made possible by a 1998 gift from the late Fritz Traugott H’98 and his wife, Frances….

Physics Professor Honored for Efforts to Improve Learning, Retention

The Department of Physics in the College of Arts and Sciences (A&S) has made some big changes lately. The department just added an astronomy major approved by New York State and recently overhauled the undergraduate curriculum to replace traditional labs with innovative…

ECS Team Takes First Place in American Society of Civil Engineers Competition

Civil and environmental engineering student teams participated in the American Society of Civil Engineers (ASCE) Sustainable Solutions and Steel Bridge competitions during the 2025 Upstate New York-Canada Student Symposium, winning first place in the Sustainable Solutions competition. The symposium was…

Chloe Britton Naime Committed to Advocating for Improved Outcomes for Neurodivergent Individuals

Chloe Britton Naime ’25 is about to complete a challenging and rare dual major program in both mechanical engineering from the College of Engineering and Computer Science and neuroscience from the College of Arts and Sciences. Even more impressive? Britton…

Subscribe to SU Today

If you need help with your subscription, contact sunews@syr.edu.

Connect With Us

For the Media

Find an Expert
© 2025 鶹ƵUniversity News. All Rights Reserved.